Freedom of information requests

Biologic medicines in Gastroenterology

Questions

Q1. How many patients were treated in the last 3 months by the Gastroenterology department (for any medical condition) with the following biologic drugs:
a) Adalimumab - Humira
b) Adalimumab Biosimilar
c) Filgotinib
d) Golimumab
e) Infliximab - Remicade
f) Infliximab Biosimilar
g) Ozanimod
h) Tofacitinib
i) Ustekinumab
j) Vedolizumab

 

Q2 If you are able to link patient treatment to a disease, could you please provide the number of patients treated in the last 3 months for Ulcerative Colitis ONLY with the following biologic drugs:
a) Adalimumab - Humira
b) Adalimumab Biosimilar
c) Filgotinib
d) Golimumab
e) Infliximab - Remicade
f) Infliximab Biosimilar
g) Ozanimod
h) Tofacitinib
i) Ustekinumab
j) Vedolizumab

Response

Please note – this response covers four hospitals.
QE = Queen Elizabeth Hospital Birmingham
HGS = Heartlands, Good Hope and Solihull Hospitals

Q1. Queen Elizabeth Hospital Birmingham 

Drug	Number of patients
a)    Adalimumab - Humira	64
b)    Adalimumab Biosimilar	3
c)    Filgotinib	1
d)    Golimumab	0
e)    Infliximab - Remicade	7
f)     Infliximab Biosimilar	0
g)    Ozanimod	0
h)    Tofacitinib	6
i)     Ustekinumab	48
j)     Vedolizumab	122

 

Q1. HGS data taken from WellSky Medicines Management dispensing data.

 

Drug	Number of patients
a)    Adalimumab - Humira	164
b)    Adalimumab Biosimilar	79
c)    Filgotinib	2
d)    Golimumab	0
e)    Infliximab - Remicade	0
f)     Infliximab Biosimilar	249
g)    Ozanimod	0
h)    Tofacitinib	42
i)     Ustekinumab	183
j)     Vedolizumab	119

 

Q2. Queen Elizabeth Hospital Birmingham 

Drug	Number of patients
a)    Adalimumab - Humira	6
b)    Adalimumab Biosimilar	0
c)    Filgotinib	0
d)    Golimumab	0
e)    Infliximab - Remicade	2
f)     Infliximab Biosimilar	0
g)    Ozanimod	0
h)    Tofacitinib	2
i)     Ustekinumab	0
j)     Vedolizumab	2

Q2. For HGS we are unable to provide data by diagnosis